Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 2Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Neoplasms 3

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Capsules × Tumor-Agnostic × Clear all
NCT04336124 2022-11-28

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

TaiRx, Inc.

Phase 1 Completed
5 enrolled
Tumor-Agnostic

Neoplasms

NCT04727138 2022-05-16

3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

Exscientia AI Limited

Phase 1 Completed
64 enrolled
Tumor-Agnostic

Neoplasms

NCT02536391 2016-11-02

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Genentech, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡